(Q37502904)

20 August 2017

1 reference

title

Mechanisms of sublingual immunotherapy. (English)

1 reference

20 August 2017

1 reference

2

Stephen Durham

1 reference

20 August 2017

Guy Scadding

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

46

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

322-334

1 reference

Long-term clinical efficacy of grass-pollen immunotherapy

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Discontinuing venom immunotherapy: outcome after five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Tregs and allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Bacillus Calmette-Guérin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Immune mechanisms of allergen-specific sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

Performance evaluation of a specific IgE assay developed for the ADVIA centaur® immunoassay system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02770900902785729

10.1080/02770900902785729

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference